导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.75% | 1420/4345 |
| 近一周 | -1.22% | 1653/4962 |
| 近一月 | -8.22% | 4402/4922 |
| 近一季 | -18.26% | 4285/4747 |
| 近半年 | -0.76% | 1432/4477 |
| 近一年 | 7.57% | 1328/4016 |
| 近两年 | 109.99% | 491/2712 |
| 近三年 | 65.26% | 369/2054 |
| 成立以来 | 34.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.63% 1893/4961 |
34.79% 947/5312 |
- - |
- - |
| 2025 | 48.40% 529/4813 |
-1.76% 2771/3635 |
3.25% 1080/4076 |
47.67% 439/4524 |
-0.93% 2725/4813 |
| 2024 | 13.08% 1182/3463 |
-3.60% 1528/2808 |
-6.21% 1884/3014 |
27.41% 225/3129 |
-1.85% 1858/3463 |
| 2023 | -17.69% 1754/2656 |
2.23% 1400/2280 |
-6.76% 1700/2385 |
-8.97% 1758/2515 |
-5.14% 1266/2655 |
| 2022 | -27.74% 1503/2207 |
-19.02% 1421/1919 |
5.82% 819/2016 |
-17.61% 1621/2113 |
2.35% 966/2208 |
| 2021 | 11.83% 395/1822 |
-6.27% 991/1255 |
24.78% 105/1330 |
-6.49% 941/1466 |
2.26% 644/1822 |
| 2020 | 62.26% 115/1250 |
3.93% 100/1028 |
28.85% 90/1067 |
5.57% 908/1164 |
14.78% 248/1184 |
| 2019 | 41.17% 237/1092 |
32.87% 158/754 |
-9.49% 660/804 |
6.98% 107/850 |
9.73% 203/918 |
| 2018 | -25.48% 354/834 |
- - |
- - |
- - |
-10.15% 179/691 |
| 2017 | -12.53% 552/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.15% 488/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘创业板ETF联接A VS. 长安沪深300非周期A(740101) |